Decreased alloreactivity after vaccination against hepatitis B. 1995

H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
Department of Pediatrics and Adolescent Medicine, University of Erlangen-Nürnberg, Germany.

The beneficial effect of blood transfusions on renal allografts disappeared at about the same time when hepatitis B vaccination was introduced in dialysis patients. To determine possible immunosuppressive effects of hepatitis B vaccination, we studied alloreactivity during the course of immunization. Fourteen healthy subjects without serological evidence of hepatitis B were routinely immunized against hepatitis B surface antigen. Plasma and mononuclear cells were isolated and frozen before immunization and after vaccination, respectively. Mean alloreactivity measured by [3H]thymidine uptake decreased from 64,772 cpm before immunization to 40,213 cpm after the third immunization. In crossover experiments, cellular modulation and plasma-dependent modulation of alloreactivity were observed. The immunosuppressive effect of plasma taken 4 weeks after the third vaccination correlated (r = 0.9) highly significantly (P < 0.005) with the anti-hepatitis B surface antigen antibody titer. Taken together, our data strongly suggest that hepatitis B vaccination is capable of reducing allogenic reactivity.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007519 Isoantigens Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS. Alloantigens,Alloantigen,Isoantigen
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D017325 Hepatitis B Vaccines Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced. Hepatitis B Vaccine,Vaccine, Hepatitis B,Vaccines, Hepatitis B
D017951 Antigen Presentation The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989) Antigen Processing,Antigen Presentations,Antigen Processings

Related Publications

H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
December 1993, Presse medicale (Paris, France : 1983),
H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
October 1996, Presse medicale (Paris, France : 1983),
H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
February 1985, Deutsche medizinische Wochenschrift (1946),
H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
February 1984, Tijdschrift voor ziekenverpleging,
H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
March 1998, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
January 1998, Sozial- und Praventivmedizin,
H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
January 1992, Atencion primaria,
H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
March 1981, Deutsche medizinische Wochenschrift (1946),
H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
January 1996, Przeglad epidemiologiczny,
H Ruder, and F Kerling, and V Daniel, and K Korn, and R Wassmuth
January 1982, Scandinavian journal of infectious diseases. Supplementum,
Copied contents to your clipboard!